Genomics

Formerly TT Capital Partners, the independent firm's new identity follows a major fundraise, sharpening its focus on healthcare IT in a competitive market.

For years, doctors dismissed her children's illness. One genetic test changed everything, revealing a truth hidden in their DNA and a flawed system.

A $2.9M investment funds five new projects using DNA and AI to clean up oil sands, secure hydrogen energy, and build a more sustainable future for Alberta.

Agena Bioscience's new test helps labs align with updated ACMG recommendations for cystic fibrosis, aiming for more equitable and efficient carrier screening.

A new partnership between Takara Bio and Hamilton promises to revolutionize RNA-seq, making high-throughput genomic analysis faster and more reliable.

After a massive breach exposed sensitive genetic data, 23andMe's Canadian settlement is final. Learn what went wrong and how to claim your share.

A US firm is bringing embryo screening for chronic diseases to major IVF networks, sparking debate on the future of family planning and genetic health.

With CE Mark approval, Countable Labs brings single-molecule counting PCR to Europe, promising unprecedented precision for gene therapy and diagnostics.

A new platform uses AI to turn complex genetic and lifestyle data into an immediate, actionable cancer prevention plan, shifting the paradigm of care.

New cardiology guidelines now include DNA risk scores, a move poised to revolutionize prevention and spot hidden threats before they strike.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

Genomic Testing Cooperative opens a Houston lab, leveraging the city's elite oncology ecosystem to expand its unique cooperative model for cancer testing.

A NY startup is using quantum computing and AI to fight aging at its source. Can Allosteric Bioscience's high-tech approach unlock a longer, healthier life?

An AI firm known for fighting cancer is now partnering with Unilever, signaling a new era of biologically personalized consumer products and new ethical questions.

Zoetis is acquiring Neogen's genomics unit for $160M, a strategic move set to accelerate data-driven innovation in livestock and companion animal care.

With star-studded advisory board, a new biotech firm aims to turn routine dental visits into a frontline defense against oral cancer.

Nautilus Biotechnology cuts losses and preps its Voyager platform for a late 2026 launch, targeting the next frontier in neurodegenerative disease research.

Nabsys's electronic genome mapping reveals how rogue genetic elements damage our DNA, opening new frontiers in understanding cancer and neurodegeneration.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.